Stockreport

Dynavax’s SD-101 in Combination with KEYTRUDA® (pembrolizumab) Continues to Show a 70% Overall Response Rate in Advanced Melanoma Patients According to Data Presented Today at the ESMO 201...

Dynavax Technologies Corporation  (DVAX) 
Last dynavax technologies corporation earnings: 3/11 04:10 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.dynavax.com
PDF - 70% overall response rate (33/47 patients) at 2 mg dose of SD-101 includes 17 additional patients - -Progression free survival, response rate in patients with PDL-1 n [Read more]